Initially, when first used by Huggins and Hodges hormone therapy (ADT) was recommended to be used early on in prostate cancer disease progression. Eventually, the Veterans Administration Cooperative Urology Research Group (VACURG) studies reversed this early recommendation. After this study ADT was usually deferred until symptomatic progression. It was believed that ADT caused an alteration [...]
In today's issue of Cancer Discovery a group of international researchers report that an investigational drug had a dramatic response in animal models of neuroendocrine prostate cancer, a lethal form of the disease. The researchers pointed out that fewer than 2% of prostate tumors in men are initially diagnosed as neuroendocrine, but many of the [...]
A study at The Cleveland Clinic has discovered that a gene – known as an androgen receptor (AR) is present in both breast and prostate cancers, but the gene has opposite effects on these diseases. The AR gene promotes prostate cancer when the gene is “turned on,” but in breast cancer the AR gene promotes [...]
According to research published today in the British Journal of Cancer, routine testing for a faulty BRCA2 gene (Kote-Jarai Z et al, BRCA2 is a gene contributing to young onset prostate cancer: implications for genetic testing in prostate cancer patients British Journal of Cancer (2011) doi:10.1038/bjc.2011.383) in men under 65 years with prostate cancer could [...]
Finally, advanced prostate cancer makes it into the genomeic world of cancer. Researchers at the Fred Hutchinson Cancer Research Center and the University of Washington in Seattle published in this week's online edition of the Proceedings of the National Academy of Sciences an announcement that they have mapped the genomes of three different types of [...]
On September 15, the Senate Committee on Appropriations approved their FY12 report by a vote of 30-0. Included in the report was their recommendations for the Department of Defense Research Programs. […]
A study by at Wake Forest Baptist Medical Center in Winston-Salem N.C., Keck School of Medicine at the University of Southern California (USC) and the Cancer Prevention Institute of California suggests that a high intake of calcium causes prostate cancer among African-American men who are genetically good absorbers of the mineral. According to Gary G. [...]
The question of today’s post is do men with advanced prostate cancer develop treatment regrets concurrent to their development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation)? To answer this question researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry [...]
Cabozantinib (cabo), has many of us prostate cancer survivor, educators and researchers simply scratching their heads. In trials, Cabozantinib demonstrated what some people have characterized as mind boggling activity against bone metastases. In trials the drug led to partial or complete resolution of bone scans in a substantial portion of patients with cancer, including prostate, [...]
It is estimated that in the United States 200,000 men will be diagnosed with prostate cancer each year with approximately 20% to 30% having clinically aggressive prostate cancer. When diagnosed the standard is to consider factors such as Gleason score and tumor stage to assess a man’s prognosis, however there are no biomarkers to identify [...]
